Related Experiment Video

Updated: Jun 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

David E Gerber1

  • 1Department of Internal Medicine, Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852.

Drug Development Research
|June 30, 2009
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors offer targeted therapy for non-small cell lung cancer (NSCLC). However, resistance to these treatments eventually develops, necessitating novel strategies for overcoming treatment failure.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted therapy using epidermal growth factor receptor (EGFR) inhibitors has emerged for non-small cell lung cancer (NSCLC).
  • These therapies are most effective in patients with EGFR-dependent tumors, often observed in females, non-smokers, East Asians, and those with adenocarcinoma.
  • Available EGFR inhibitors include oral tyrosine kinase inhibitors (TKIs) and intravenous monoclonal antibodies (mAbs).

Purpose of the Study:

  • To review the efficacy and limitations of current EGFR inhibitors in NSCLC treatment.
  • To explore mechanisms of resistance to EGFR-targeted therapies.
  • To discuss strategies for overcoming acquired resistance to EGFR inhibitors.

Main Methods:

  • Review of current literature on EGFR inhibitors in NSCLC.
  • Analysis of clinical trial data regarding TKI and mAb efficacy.
  • Discussion of molecular mechanisms underlying EGFR inhibitor resistance.

Main Results:

  • EGFR TKIs prolong survival as monotherapy in metastatic NSCLC but offer no benefit when combined with chemotherapy.
  • The anti-EGFR mAb cetuximab shows efficacy when combined with chemotherapy or radiation.
  • NSCLC tumors frequently develop resistance to EGFR inhibition through various mechanisms.

Conclusions:

  • EGFR inhibitors represent a significant advancement in NSCLC treatment, particularly for specific patient populations.
  • Understanding resistance mechanisms is crucial for developing effective therapeutic strategies.
  • Future research should focus on novel combinations and next-generation inhibitors to overcome resistance and improve patient outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...